Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect Supernus Pharmaceuticals to post earnings of $0.37 per share for the quarter.
Supernus Pharmaceuticals Stock Performance
Shares of Supernus Pharmaceuticals stock traded up $0.37 on Monday, reaching $32.07. 125,028 shares of the company's stock were exchanged, compared to its average volume of 492,647. The company has a market capitalization of $1.80 billion, a P/E ratio of 29.96 and a beta of 0.74. Supernus Pharmaceuticals has a 52 week low of $25.53 and a 52 week high of $40.28. The firm's 50-day moving average is $31.86 and its two-hundred day moving average is $34.90.
Insiders Place Their Bets
In other news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 9.30% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on SUPN. StockNews.com lowered shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Thursday. Cantor Fitzgerald reissued a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.
Read Our Latest Analysis on Supernus Pharmaceuticals
About Supernus Pharmaceuticals
(
Get Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Featured Articles
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
